Abemaciclib monotherapy for treating advanced hormone-receptor positive, HER2-negative breast cancer after endocrine therapy and chemotherapy [ID1347]
Discontinued
Reference number: GID-TA10264
As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of abemaciclib monotherapy for treating advanced hormone-receptor positive, HER2-negative breast cancer after endocrine therapy and chemotherapy.
However, following on from advice received from the company, NICE has decided to suspend this appraisal from its work programme.
As this appraisal has been referred, NICE will continue to monitor any development and will update interested parties if the situation changes.